Adjuvant tislelizumab

DRUG2 trials

Sponsors

Guangxi Medical University, Tianjin Medical University Cancer Institute and Hospital

Conditions

Hepatocellular CarcinomaImmune Checkpoint InhibitorNSCLC (Non-small Cell Lung Cancer)Recurrence

Phase 2

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

RecruitingNCT06939127

Tianjin Medical University Cancer Institute and HospitalNSCLC (Non-small Cell Lung Cancer)

Start: 2025-04-01End: 2027-05-31Target: 38Updated: 2025-04-22

Phase 3

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Not yet recruitingNCT05910970

Guangxi Medical UniversityHepatocellular Carcinoma, Immune Checkpoint Inhibitor, Recurrence

Start: 2024-02-15End: 2025-12-31Target: 200Updated: 2024-01-23